Merck stock trades steady as Keytruda growth offsets patent cliff concerns

Merck & Co., Inc. (ISIN US58933Y1055) remains a core large cap in US healthcare, and Merck stock continues to be shaped by a combination of strong oncology growth and looming patent expiries for its flagship therapy Keytruda. As of 30 July 2026, major financial portals show Merck with a market capitalization in the neighborhood of tens of billions of US dollars, anchoring its role in the S&P 500 and Nasdaq-quoted US pharma space. The latest quarterly results highlighted how rising oncology revenue is helping to balance declines in certain mature products, with investors closely tracking both the near term earnings picture and the longer term pipeline that will need to carry the business beyond Keytruda’s eventual loss of exclusivity.

Keytruda drives double digit revenue

In the most recent reported quarter, according to Merck’s own investor materials available via its corporate investor relations website, total company revenue reached many billions of US dollars, with oncology once again the central growth engine. Keytruda, Merck’s PD-1 checkpoint inhibitor for a range of cancers, delivered double digit year on year revenue growth in that quarter, lifting oncology segment sales meaningfully compared with the prior period. This rise compared with the same quarter a year earlier showed that demand for immuno-oncology therapies remains firm, and it underscored Merck’s position as one of the largest global suppliers of cancer medicines.

Merck’s investor relations disclosures also show that adjusted earnings per share for the latest quarter came in at a level that reflected solid profitability after research and development and marketing expenses. The company reported year on year growth in adjusted EPS compared with the prior year quarter, a sign that higher revenue and careful cost management are translating into bottom line gains even as Merck continues to invest heavily in clinical trials and regulatory filings for new therapies. The operating margin for the period improved versus the previous year, supported by scale effects in oncology and efficiency measures in manufacturing and commercial operations.

Revenue up compared with prior year

In its latest annual report and associated earnings materials, Merck outlined that full year revenue for the preceding fiscal year reached a multi tens of billions US dollar level. This represented an increase compared with the prior fiscal year, with Keytruda and other growth products more than offsetting declines from products facing generic competition. The quantified comparison versus the previous year illustrates that Merck is still in a growth phase overall, even though parts of its portfolio are mature.

The company also disclosed that net income for the fiscal year improved compared with the previous year, reflecting not only higher sales but also disciplined expense control. Free cash flow generation was strong over the year, giving Merck continued flexibility to fund dividends, share repurchases, bolt on acquisitions and large scale research programs. In this context, investors often note that Merck’s balance sheet, as described in its annual filings, shows manageable net debt relative to EBITDA, which supports an investment grade credit profile and offers resilience against potential macroeconomic volatility.

Keytruda and oncology portfolio

Keytruda is central to Merck’s commercial profile, both from a revenue and from a strategic standpoint. The drug is approved in numerous indications across melanoma, lung cancer, head and neck cancer and other tumor types, often in combination with chemotherapy or other agents. In recent years, Merck has announced positive data from several pivotal trials demonstrating improved progression free survival and overall survival compared with standard therapies, helping to expand the drug’s label incrementally.

In the latest quarter and year, according to Merck’s published data on its oncology business, Keytruda’s revenue share of total company sales rose compared with earlier periods. That increased concentration is an important point for investors, because it underlines both Merck’s competitive strength in immuno-oncology and the concentration risk associated with a single product generating a substantial portion of overall revenue. In response, Merck continues to highlight its broader oncology pipeline, including combinations with novel agents and new biomarker driven approaches intended to sustain its franchise as competitors bring their own immunotherapies to market.

Pipeline, patent outlook and diversification

Beyond Keytruda, Merck has emphasized, in its investor presentations and earnings calls, its work on earlier stage assets in oncology, vaccines and cardiovascular disease. The pipeline includes several phase three candidates aimed at addressing high unmet need areas. Successful data from these trials, if confirmed and approved by regulators, could provide new sources of revenue to diversify the portfolio before Keytruda faces major patent expiries in key jurisdictions.

The patent cliff is a central theme for Merck stock. Analysts and investors frequently discuss the timeline around Keytruda’s loss of exclusivity and the potential entry of biosimilar competitors. Merck’s management has responded by stepping up business development transactions, including licensing deals and targeted acquisitions, to strengthen both oncology and non oncology areas. This strategy, reflected in past deal announcements, aims to balance the portfolio and ensure that future topline growth and cash flow do not rely exclusively on Keytruda beyond the end of its patent life.

Merck also maintains a large vaccines business, including well known products in pediatric and adult immunization. This segment contributes meaningful recurring revenue and tends to be more stable across economic cycles than some other pharmaceutical lines. In addition, the company has therapies in hospital acute care, infectious disease and animal health, all of which provide diversification at a time when investors are particularly focused on how Merck can mitigate concentration risk.

Product focus Keytruda immunotherapy

Among Merck’s broad portfolio, Keytruda stands out as a representative product for the company’s current success. The PD-1 inhibitor has become a standard of care in multiple cancers, and its clinical profile has been built over many years of data collection and regulatory engagement. For patients, Keytruda offers a targeted mechanism of action that harnesses the immune system to attack cancer cells, and for Merck it offers a platform around which combination therapies can be constructed.

In financial terms, Keytruda’s revenue line increasingly sets the tone for Merck’s quarterly reports. When the drug grows at double digit rates year on year, it often drives overall revenue higher even if other segments are flat or declining. Conversely, any slowdown in Keytruda’s growth trajectory would be closely scrutinized by investors, given the product’s importance. Merck’s long term planning therefore revolves around continuing to expand the drug’s indications while simultaneously building new sources of growth that can stand alongside Keytruda over time.

Merck stock and market positioning

Merck stock is listed on the New York Stock Exchange in US dollars and is a component of the S&P 500 index. The share price, as reported by major market data portals for late July 2026, trades in a range that reflects investor expectations about continued earnings growth, balanced against the known future patent challenges. Some market commentary notes that Merck’s valuation metrics, such as price to earnings ratios based on forward earnings estimates, place it among the large cap pharma names that are seen as relatively defensive compared with more volatile growth sectors.

For shareholders, Merck’s consistent dividend payments and share repurchase programs, as disclosed in its annual and quarterly materials, provide an ongoing return component alongside potential capital gains from share price movements. The company’s ability to fund these distributions rests on its strong cash generation, which in turn depends on sustaining revenue growth and protecting margins. As Merck moves further into the second half of the decade, the interplay between its flagship oncology therapy, its emerging pipeline, and its broader diversified portfolio will continue to shape Merck stock’s behavior on the NYSE.